Additional Information
for Healthcare Personnel

About the Study Medication

The study medication is a small-molecule TRPC ion channel inhibitor. The study medication works by blocking the activity of transient receptor potential channels (TRPC), specifically TRPC3, TRPC6, and TRPC7. These channels play a role in regulating the movement of molecules such as calcium across cell membranes, which is critical to various cellular processes. By inhibiting TRPC activity, the study medication may help prevent cellular mechanisms that lead to heart cell death, potentially offering protection during ischaemic reperfusion injury.

In a Phase 1 trial involving healthy volunteers, the study medication was administered as an intravenous infusion for up to six hours. The study demonstrated that the study medication was safe and well tolerated. Preclinical studies also showed strong efficacy in reducing cardiovascular damage caused by myocardial ischemia-reperfusion injury.

Additional Inclusion/exclusion criteria

Inclusion criteria

Main inclusion criteria includes male and female participants who are experiencing their first STEMI and are not of child-bearing potential.

Exclusion criteria

Main exclusion criteria includes: prior cardiac surgery, body weight less than 50 kg or greater than 120 kg, as well as any medical condition or abnormality that, in the opinion of the Investigator, would make study participation unsafe.

Study Schema